Nanobiotix - ADR Stock News

PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:

Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached] Median Local Progression-Free Survival of 13.3 months from completion of radiation Notable findings observed in explorator...

PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of full results from the completed dose escalation and d...

Nanobiotix S.A. (NASDAQ:NBTX ) Q4 2024 Results Conference Call April 3, 2025 8:00 AM ET Company Participants Craig West - Senior Vice President, Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chief Financial and Business Officer Conference Call Participants Yen-Der Li - Leerink Partners Shan Hama - Jefferies Michael Schmidt - Guggenheim Securities Art ...

Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Disciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milest...

Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST

PARIS and CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering disruptive, nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today announced the first data from the completed dose escalation part of a Phase 1 study sponsored by The Universi...

PARIS and CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced poster presentations from two Phase 1 studies evaluating JNJ-1900 (NBTXR3...